|
1
|
Nagaiah G, Hossain A, Mooney CJ,
Parmentier J and Remick SC: Anaplastic thyroid cancer: A review of
epidemiology, pathogenesis, and treatment. J Oncol.
2011:5423582011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molinaro E, Romei C, Biagini A, Sabini E,
Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini
A, et al: Anaplastic thyroid carcinoma: From clinicopathology to
genetics and advanced therapies. Nat Rev Endocrinol. 13:644–660.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fagin JA and Wells SA Jr: Biologic and
Clinical Perspectives on Thyroid Cancer. N Engl J Med.
375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janz TA, Neskey DM, Nguyen SA and Lentsch
EJ: Is the incidence of anaplastic thyroid cancer increasing: A
population based epidemiology study. World J Otorhinolaryngol Head
Neck Surg. 5:34–40. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Simeone P, Trerotola M, Franck J, Cardon
T, Marchisio M, Fournier I, Salzet M, Maffia M and Vergara D: The
multiverse nature of epithelial to mesenchymal transition. Semin
Cancer Biol. 58:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsiambas E, Ragos V, Georgakopoulos G,
Rigopoulos DN, Fotiades PP, Chatziioannidis A, Stamatelopoulos A,
Vilaras G and Karameris A: E-cadherin/α-catenin deregulated
co-expression in thyroid carcinoma based on tissue microarray
digital image analysis. J Buon. 21:450–5. 2016.PubMed/NCBI
|
|
7
|
Fourati A, El Amine O, Ben Ayoub W, Cherni
I, Goucha A, El May MV, Gamoudi A and El May A: Expression profile
of biomarkers altered in papillary and anaplastic thyroid
carcinoma: Contribution of Tunisian patients. Bull Cancer.
104:433–441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Xu L, Li A and Han X: The roles
of ZEB1 in tumorigenic progression and epigenetic modifications.
Biomed Pharmacother. 110:400–408. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yao X, Sun S, Zhou X, Zhang Q, Guo W and
Zhang L: Clinicopathological significance of ZEB-1 and E-cadherin
proteins in patients with oral cavity squamous cell carcinoma. Onco
Targets Ther. 10:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan T, Zhang T, Si X and Zhou Y:
Overexpression of EMT-inducing transcription factors as a potential
poor prognostic factor for hepatocellular carcinoma in Asian
populations: A meta-analysis. Oncotarget. 8:59500–59508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harb OA, Elfeky MA, El Shafaay BS, Taha
HF, Osman G, Harera IS, Gertallah LM, Abdelmonem DM and Embaby A:
SPOP, ZEB-1 and E-cadherin expression in clear cell renal cell
carcinoma (cc-RCC): Clinicopathological and prognostic
significance. Pathophysiology. 25:335–345. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng X, Wang Z, Fillmore R and Xi Y:
miR-200, a new star miRNA in human cancer. Cancer Lett. 344:166–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fuziwara CS and Kimura ET: MicroRNA
deregulation in anaplastic thyroid cancer biology. Int J
Endocrinol. 2014:7434502014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Enomoto K, Sato F, Tamagawa S, Gunduz M,
Onoda N, Uchino S, Muragaki Y and Hotomi M: A novel therapeutic
approach for anaplastic thyroid cancer through inhibition of LAT1.
Sci Rep. 9:146162019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta C(T)) method. Methods. 25:402–8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Das V, Bhattacharya S, Chikkaputtaiah C,
Hazra S and Pal M: The basics of epithelial-mesenchymal transition
(EMT): A study from a structure, dynamics, and functional
perspective. J Cell Physiol. 2019.(Epub ahead of print). View Article : Google Scholar
|
|
18
|
Caramel J, Ligier M and Puisieux A:
Pleiotropic Roles for ZEB1 in Cancer. Cancer Res. 78:30–35. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sekiguchi M, Shiroko Y, Arai T, Kishino T,
Sugawara I, Kusakabe T, Suzuki T, Yamashita T, Obara T, Ito K and
Hasumi K: Biological characteristics and chemosensitivity profile
of four human anaplastic thyroid carcinoma cell lines. Biomed
Pharmacother. 55:466–74. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Danielsson F, Peterson MK, Caldeira Araújo
H, Lautenschläger F and Gad AKB: Vimentin diversity in health and
disease. Cells. 7:1472018. View Article : Google Scholar
|
|
22
|
Garg M: Epithelial, mesenchymal and hybrid
epithelial/mesenchymal phenotypes and their clinical relevance in
cancer metastasis. Expert Rev Mol Med. 19(e3)2017.PubMed/NCBI
|
|
23
|
Mongroo PS and Rustgi AK: The role of the
miR-200 family in epithelial-mesenchymal transition. Cancer Biol
Ther. 10:219–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Braun J, Hoang-Vu C, Dralle H and
Hüttelmaier S: Downregulation of microRNAs directs the EMT and
invasive potential of anaplastic thyroid carcinomas. Oncogene.
29:4237–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Liu ZB, Ren WM, Ye XG and Zhang
YY: The miR-200 family regulates the epithelial-mesenchymal
transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
Int J Mol Med. 30:856–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jensen K, Patel A, Hoperia V, Larin A,
Bauer A and Vasko V: Dynamic changes in E-cadherin gene promoter
methylation during metastatic progression in papillary thyroid
cancer. Ther Med. 1:457–462. 2010. View Article : Google Scholar
|
